Company Encyclopedia
View More
name
AK MEDICAL
01789.HK
AK Medical Holdings Limited, an investment holding company, designs, develops, produces, and markets orthopedic joint implants and related products in the People’s Republic of China and internationally. It offers knee, hip, and spinal and trauma replacement implants; and 3D-printed products, such as 3D-printed hip and knee replacement implants, 3D-printed spinal and trauma implants, and customized products and services. The company also distributes third party orthopedic products; and offers surgical instruments and medical irrigators. Its principal customers include distributors, hospitals, physicians and surgeons, and patients.
133.60 B
01789.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking3/26
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE11.31%B
    • Profit Margin21.34%A
    • Gross Margin59.11%B
  • Growth ScoreA
    • Revenue YoY25.70%A
    • Net Profit YoY56.65%B
    • Total Assets YoY14.25%B
    • Net Assets YoY11.74%B
  • Cash ScoreB
    • Cash Flow Margin468.53%C
    • OCF YoY25.70%A
  • Operating ScoreC
    • Turnover0.41C
  • Debt ScoreB
    • Gearing Ratio23.26%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Understanding the Market | AK MEDICAL currently rises over 6% as the centralized procurement renewal policy is fully implemented, and performance in the second half of the year is expected to accelerate

    AK MEDICAL is currently up over 6%, as of the time of writing, up 4.34%, priced at HKD 6.25, with a transaction volume of HKD 32.2594 million. CITIC Construction Investment released a research report stating that looking ahead to the second half of 2025, as the national implementation of the artificial joint centralized procurement renewal policy is fully rolled out, the industry's pricing system is expected to stabilize. The company has seen an increase in the bid prices for hip and knee joints in this round of renewal, and the logic of rising volume and price is expected to be realized. At the same time, the surgical volume in the orthopedic industry is expected to recover, and the company's revenue base in the second half of last year was not high, so it is expected that the company's performance will show a trend of low in the front and high in the back this year, with rapid growth expected in the second half. The report pointed out that in the medium to long term, the company's forward-looking layout in innovative products such as 3D printing and surgical robots, as well as the digital orthopedic ecosystem, will build a solid technological barrier and open up new growth space; in overseas markets, with the deepening of the "JRI + AK MEDICAL" dual-brand strategy and the continuous advancement of product registration, overseas business is expected to become a strong growth engine for the company

    Zhitong·
    HK
    01789
    -0.36%
    Zhitong·
    HK
    01789
    -0.36%

    Understanding the Market | AK MEDICAL rose over 9% in the morning as centralized procurement accelerates import substitution and high-end hospital coverage, with significant international growth potential for the company

    AK MEDICAL rose over 9% in the morning, and as of the time of publication, it was up 8.73%, trading at HKD 5.98, with a transaction volume of HKD 74.485 million. CITIC Construction Investment released a research report stating that in the national procurement of artificial joints, AK MEDICAL has steadily increased its market share due to its cost-effectiveness and localized service advantages, accelerating the replacement of imports and coverage of high-end hospitals. Relying on the iCOS digital orthopedic platform, the company has built a full-process solution of "preoperative planning - intraoperative navigation - postoperative monitoring." With the approval and market launch of its self-developed K3 intelligent surgical robot, digital products and implants are expected to synergistically increase in volume. Internationalization is the company's second growth curve; through the "AK MEDICAL + JRI" dual-brand strategy, the company effectively covers different overseas markets, with the proportion of overseas revenue gradually increasing and significant growth potential. The report continues to indicate that looking ahead to the second half of 2025, as the procurement renewal policy for artificial joints is fully implemented nationwide, the industry's pricing system is expected to stabilize. The company has seen an increase in the bid prices for hip and knee joints in this round of renewals, and the logic of rising volume and price is expected to be realized. At the same time, the surgical volume in the orthopedic industry is expected to recover, and the company's revenue base in the second half of last year was not high, so it is expected that the company's performance will show a trend of low in the front and high in the back this year, with rapid growth expected in the second half

    Zhitong·
    HK
    01789
    -0.36%
    Zhitong·
    HK
    01789
    -0.36%

    AK Medical Holdings Reports 5.6% Rise in Revenue and 15.3% Increase in Profit for H1 2025

    AK Medical Holdings reported a 5.6% rise in revenue to RMB694.2 million for H1 2025, compared to RMB657.1 million in H1 2024. Gross profit increased by 3.0% to RMB410.3 million, while profit for the period rose 15.3% to RMB160.6 million. The gross margin decreased to 59.1% from 60.6% year-on-year. Cost of sales rose by 9.8% to RMB283.9 million, and other income surged to RMB18.3 million from RMB2.9 million in the previous year. Selling and distribution expenses increased by 3.8% to RMB117.3 million.

    Reuters·
    HK
    01789
    -0.36%
    Reuters·
    HK
    01789
    -0.36%

    Cathay Securities and Haitong Securities: Maintain AK MEDICAL's "Buy" rating with a target price of HKD 8.26

    CITIC Securities maintains a buy rating on AK MEDICAL, with a target price of HKD 8.26. In the first half of 2025, AK MEDICAL achieved revenue of 694 million yuan, a year-on-year increase of 5.6%, and a net profit attributable to the parent company of 161 million yuan, a year-on-year increase of 15.3%. Overseas revenue grew by 4.0% year-on-year to 128 million yuan, and is expected to accelerate in the second half of the year. The company continues to make breakthroughs in the domestic market, especially in clinical applications in high-end hospitals. The spinal business is affected by policies, while the digital orthopedic business remains stable

    Zhitong·
    HK
    01789
    -0.36%
    Zhitong·
    HK
    01789
    -0.36%

    AK MEDICAL released its interim results, with profit attributable to shareholders of 161 million yuan, an increase of 15.34% year-on-year

    According to the Zhitong Finance APP, AK MEDICAL released its interim results for the six months ended June 30, 2025, with revenue of 694 million yuan (RMB, the same below), an increase of 5.65% year-on-year; the profit attributable to shareholders was 161 million yuan, an increase of 15.34% year-on-year, with basic earnings per share of 0.14 yuan

    Zhitong·
    HK
    01789
    -0.36%
    Zhitong·
    HK
    01789
    -0.36%
    © 2025 Longbridge｜Disclaimer